BioXcel Therapeutics, Inc. (BTAI) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net Revenue from Sales of IGALMI Dexmedetomidine Sublingual Film | 206K | FY2026-Q1 |
| SERENITY At-Home Phase 3 Trial Agitation Episodes Collected | 2.63K | FY2025-Q3 |
| SERENITY At-Home Phase 3 Trial Enrolled Patients | 200.00 | FY2025-Q2 |
Back to BTAI overview · BTAI earnings · BTAI holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.